Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ziltivekimab · COR-001, MEDI-5117

Monoclonal antibody · developed by Novo Nordisk

Phase 3 Most advanced trial
NVO Developer

What is Ziltivekimab?

Ziltivekimab is a subcutaneously administered once-monthly agent studied in heart failure and systemic inflammation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
COR-001, MEDI-5117
Drug type
Monoclonal antibody
Therapy area
Cardiovascular
Developer
Novo Nordisk A/S (NVO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
AN3Y2B4SX4

Conditions studied

Heart FailureSystemic Inflammation

More from Novo Nordisk

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NVO page.

Follow NVO, the company behind Ziltivekimab

See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.